Agalsidase Alfa (Replagal)

Agalsidase alfa is the enzyme-replacement therapy this site's own agalsidase beta and pegunigalsidase alfa pages both mention in passing but don't cover directly — a second recombinant alpha-galactosidase A approved for Fabry disease, and the one drug in that cluster that has never reached the US market. Developed by the Massachusetts biotech Transkaryotic Therapies (TKT), the European Union approved it as Replagal in August 2001, months ahead of Fabrazyme's 2003 US approval, and it's since been approved in more than 70 countries and remains a mainstay Fabry treatment across Europe, Canada and elsewhere. Shire, which acquired TKT in 2005 (later itself acquired by Takeda), tried repeatedly to bring Replagal to the US too, but withdrew its FDA application in 2012 after the agency indicated it would require additional controlled trials — leaving agalsidase alfa as a real, decades-old, widely-used approved medicine everywhere except the country whose own Fabrazyme shortage, a few years earlier, sent hundreds of European patients switching onto it instead.

A second Fabry enzyme, approved in Europe before Fabrazyme was approved in the US

This site's agalsidase beta page describes Fabry disease — a rare, X-linked disorder in which deficient alpha-galactosidase A activity lets a fatty molecule, globotriaosylceramide (GL-3), accumulate in blood vessels throughout the body, driving progressive kidney damage, cardiac thickening and stroke risk. Agalsidase alfa is a second, independently developed recombinant form of the same missing enzyme, originally developed by the Massachusetts biotech Transkaryotic Therapies (TKT) in a genetically engineered human cell line rather than the Chinese hamster ovary cells used for agalsidase beta. The European Commission approved it under the brand name Replagal in August 2001 — making it, not Fabrazyme, the first Fabry disease treatment approved anywhere, nearly two years before agalsidase beta reached the US market in April 2003. Shire acquired TKT for roughly $1.6 billion in a deal completed in July 2005, taking over Replagal and rebranding TKT as Shire Human Genetic Therapies; Shire was in turn acquired by Takeda in a deal that closed in January 2019, so Replagal has changed corporate hands twice since its original approval without ever leaving the market. Replagal is dosed differently too: 0.2 mg/kg by IV infusion every two weeks, a fifth of agalsidase beta's 1 mg/kg dose, reflecting a genuinely different development program rather than a simple copy of its rival.

The pivotal trial: pain, kidney tissue, and a lower dose

Agalsidase alfa's pivotal evidence came from a double-blind, placebo-controlled trial run at the US National Institutes of Health, enrolling 26 adult men with Fabry disease who received either 0.2 mg/kg agalsidase alfa or placebo every two weeks for six months (12 doses). The trial's primary endpoint was clearance of GL-3 deposits from kidney microvascular endothelium on biopsy, which improved significantly more with agalsidase alfa than placebo; treated patients also reported significantly reduced neuropathic pain and pain-medication use, and improved pain-related quality of life, though later methodological critiques noted a baseline imbalance in pain scores between the two study arms that complicates how cleanly that specific secondary finding can be read (Schiffmann R, Kopp JB, Austin HA 3rd, et al., "Enzyme replacement therapy in Fabry disease: a randomized controlled trial," JAMA 2001;285(21):2743-2749, PMID 11386930, DOI: 10.1001/jama.285.21.2743).¹ A separate, later head-to-head comparison of agalsidase alfa and agalsidase beta, both given at the same 0.2 mg/kg dose, found broadly similar biochemical and functional effects between the two enzymes at that matched dose — evidence cited in the long-running clinical debate over whether the two drugs' different approved doses reflect a genuine efficacy difference or simply two separate companies settling on different regulatory strategies (Vedder AC, Linthorst GE, Houge G, et al., "Treatment of Fabry Disease: Outcome of a Comparative Trial with Agalsidase Alfa or Beta at a Dose of 0.2 mg/kg," PLoS One 2007;2(7):e598, PMID 17622343, DOI: 10.1371/journal.pone.0000598).²

2009: the shortage that sent hundreds of patients onto it

Why it was never approved in the US

Shire submitted a Biologics License Application for Replagal to the FDA more than once over the 2000s, but each attempt stalled. On 14 March 2012, Shire formally withdrew its pending US application, stating publicly that recent discussions with the FDA had led the company to conclude the agency would require additional, large-scale controlled clinical trials before it would approve the drug — trials that, given how few Fabry patients exist to enroll (an ultra-rare disease already split across multiple approved and investigational therapies by that point), Shire judged would take years to complete with no guarantee of a different outcome. The FDA did not cite any specific safety concern with Replagal itself in the public record of the withdrawal; contemporaneous trade reporting characterized the issue as a gap in confirmatory efficacy data from a US-based trial population rather than a finding against the drug. The withdrawal left Fabrazyme (and, from 2018, the oral chaperone migalastat) as the only FDA-approved Fabry treatment options in the US, even as Replagal continued to be prescribed as a mainstream, government-reimbursed treatment across the EU, UK, Canada, and dozens of other countries throughout the same period.

Current status

Replagal remains approved and actively marketed by Takeda (which acquired Shire in 2019) in more than 70 countries, per the company's own regulatory disclosures as of early 2023, and continues to be prescribed alongside agalsidase beta and, more recently, pegunigalsidase alfa as one of several enzyme-replacement options available to Fabry patients outside the US. It has never been resubmitted for FDA approval since the 2012 withdrawal, and no public Takeda statement as of this review commits to a renewed US filing — Fabry patients in the US remain limited to agalsidase beta, pegunigalsidase alfa, and the oral chaperone migalastat for patients with an amenable mutation, a narrower set of choices than exists almost everywhere else agalsidase alfa is sold.